


Advances in Biomaterial Design and Application for Glaucoma Therapy

Jui-Yang Lai, Ph.D.

Department of Biomedical Engineering,
Chang Gung University, TAIWAN

Functional Biomaterial Lab



CHANG GUNG UNIVERSITY, TAIWAN




CGU FB CGU IG CGU International

2022 Best Overall In Taiwan

CWUR WORLD UNIVERSITY RANKINGS **#579** **#6**

Research Interest


- Ophthalmic Biomaterials
- Drug Delivery
- Nanomedicine
- Tissue Engineering




CONTROLLED RELEASE SOCIETY
CRS 2023 ANNUAL MEETING & EXPOSITION
JULY 24-28, 2023 **Paris Hotel** » **Las Vegas, NV, USA**

THE FUTURE OF DELIVERY SCIENCE


Eye




Eye: Community Life



<http://www.nei.nih.gov/health/eyediagram/eyeimages4.asp>



2nd global leading cause of blindness




http://www.who.int/Blindness/Vision2020_report.pdf


Glaucomatous Case Number ↑

Glaucoma: Feature

- Elevated eye pressure
(**> 21 mmHg**)




Retinal ganglion cell apoptosis




https://edc2.healthtap.com/ht-staging/user_answer/avatars/1106716/large/open-uri20130505

Glaucoma: Outcome




Optic nerve depression




<https://www.cceye.com.tw/eyecare/view/446>

Ophthalmic Drug Formulations



Functional biomaterial carrier as DDS






Short, Toxicol. Pathol. 2008;36:49-62

■ **Injectable Thermogel**

■ **Nanoceria Eye Drop**




→ Improve bioavailability

→ Completely alleviate symptoms



Synthesis of gelatin-g-PNIPAAm


Intraocular Pressure & Pupil Diameter



- GN-Drug: significant decreases in IOP & pupil diameter were noted over 2 weeks, suggesting **intense pharmacological activity** and **high ocular drug bioavailability**

Next Stage

- Our findings support the hypothesis that the combination of **degradable** with **temperature-sensitive** features of carriers increases drug delivery performance



Extended Release






Functional Boost

Extended Release

Chain Length of Monothiol-Terminated Alkyl Carboxylic Acid


Carbon number of PN segment

In vivo release profile




Glaucomatous damage

Acta Biomater. 2017;49:344-357




Functional Boost


Cytoprotective Antiglaucoma DDS



GA Grafting Effect




Improved Antioxidant




Biomacromolecules 2015;16:2950-2963

Glaucomatous Optic Neuropathy

A Normal anatomy



B Neurodegenerative changes associated with glaucomatous optic neuropathy




JAMA 2014;311:1901-1911

Dr. Fatunmbi C. Lynn


- The optic disc is composed of neural, vascular, and connective tissues
- Glaucomatous optic neuropathy involves damage and remodeling of the optic disc tissues and lamina cribrosa that lead to vision loss

Prooxidant/Antioxidant Balance




J. Control. Release 2020;317:246-258


Characterization




3,4,5-trihydroxybenzoic acid
(THB)




3,4-dihydroxy-5-methoxybenzoic acid
(MB)










4-hydroxy-3,5-dimethoxybenzoic acid
(p-DMB)



3-hydroxy-4,5-dimethoxybenzoic acid
(m-DMB)



3,4,5-trimethoxybenzoic acid
(TMB)










■ Increasing the number of methylation of OH groups induces a **hypsochromic shift**




■ An additional spectral peak was noted in the range of 7.0-7.5 (**2H, s, 2-H and 6-H**) ppm

Cellular Response

THB has **strong** antioxidant activity but also could act as **pro-oxidant**




In Vivo Study





Ac
H4

In Vivo Study











Glaucomatous eye







Nanocapsular System

Polyester-Based Hollow Nanocarrier







Nanoscale 2017;9:11754-11764

Eye Drop




Biomaterials 2020;243:119961



Characterization





Functional Assay




Anti-Oxidant





Anti-Inflammator









TJ Opening




Cell Targeting



In Vivo Study




Effect of Shell Thickness



Theranostics 2021;11:5447-5463

Effect of Chitosan DD


Amination-Mediated Drug Delivery Performance for Acute Glaucoma Therapy



Chem. Eng. J. 2023;451:138620

Concluding Remarks

- Our findings suggest that multifunctional biomaterials may have potential for application as **injectable depot** or **eye drop** formulation for intraocular drug delivery
- Structure-property-function relationship can be tailored to the needs of **therapeutic DDS** for treating ocular diseases



Acknowledgments


Group member: graduate students

Financial support: NSTC & NHRI


Disease Treatment: DDS/ITNP

The development of efficient therapies for ocular diseases remains a significant challenge because of the static and dynamic barriers in the eye. A variety of pharmaceutical strategies have been explored to overcome these ocular physiological barriers and thereby improve therapeutic bioavailability in both anterior and posterior ocular tissues. This mini-review summarizes, analyzes, and discusses recent advances in the field of ophthalmic drug delivery systems (DDSs). Specifically, the focus is on design strategies using stimuli-responsive polymers and their applications for the treatment of prevalent ocular diseases such as dry eye, ocular infection, glaucoma, and age-related macular degeneration. The stimuli-responsive polymers are categorized according to their responses in various ocular environmental conditions (such as temperature, pH, and ions). Additionally, general strategies and methodologies for the construction of effective ophthalmic stimuli-responsive DDSs are investigated by exploiting key parameters such as the stimuli-response type, ocular biocompatibility, ocular biodegradability, drug encapsulation and release, as well as the modifiable structure of the polymers. Also discussed in this review are the interrelationships among the designed structures, properties, and functions of the stimuli-responsive DDSs and their pharmacological treatment efficacies. In summary, we believe that the recent progress in the field of stimuli-responsive DDSs constitutes a significant advance for the development of effective pharmacological treatments for eye disorders.

[Polymer Chemistry Pioneering
Investigators Issue]










[WOS Highly Cited Paper]




Intrinsically therapeutic nanoparticles (ITNPs) are a special class of nanomaterials with capabilities of self-triggering bioactive activities (without drug) when interacting with biological entities of interest. Typical bioactive features of ITNPs are antioxidant, antiinflammatory, antiangiogenic, and antibacterial properties, which can be medicinally exploited to treat a variety of diseases. Recently, ITNPs have considerably contributed to the development of numerous therapeutic modalities, simplified the formulation of nanotherapeutics, and promoted the translations of these intriguing biomaterials from bench to bedside. Therefore, this review summarizes, analyzes, and discusses recent advances of ITNPs in the treatment of diseases associated with four main risk factors: oxidative stress, inflammation, angiogenesis, and infection. Specifically, an update on the syntheses, bioactive properties, and biomedical assessments of ITNPs is provided. Moreover, therapeutic efficacies of ITNPs in pre/clinical trials are deliberated with respect to their physical/chemical characteristics; challenges and perspectives toward the clinical translation of ITNPs are also highlighted.

Macular Degeneration: Nanotherapeutics



ACS Nano 2023;17:168-183

Corneal Alkali Burn: Nanomedicine



Adv. Sci. 2023;10:e2302174